NIH’s Recombinant DNA Advisory Committee
Executive Summary
Will discuss costs for injuries sustained during non- therapeutic gene research in patients on the first day of its Dec. 3-4 meeting. RAC also will consider protocols for three cystic fibrosis gene therapy studies and one autologous bone marrow transplantation gene therapy trial, and amendments to the several gene therapy "points to consider" documents. The meeting begins at 9 a.m. on Dec. 4 and 8:30 a.m. on Dec. 4 in Wilson Hall, Bldg. One, on the NIH campus.